TY - JOUR
T1 - Does accepting pharmacokinetic recommendations impact hospitalization? A cost-benefit analysis
AU - Destache, Christopher J.
AU - Meyer, Sharon K.
AU - Rowley, Karen M.
PY - 1990/9
Y1 - 1990/9
N2 - In a prospective, randomized study, 110 adults receiving aminogly-cosides were randomized to follow-up by a clinical pharmacokinetic service (CPS). Of the 110 patients, 35 accepted pharmacokinetic recommendations less than 100% of the time. The two groups were similar in age, sex, height, APACHE II score, and initial creatinine clearance. A cost-to-charge ratio was used to derive direct costs of hospitalization and calculate cost-benefit. Patients whose physicians accepted pharmacokinetic recommendations 100% of the time had shorter hospitalizations (322.67 ± 270.28 h; CPS <100%, 699.54 ± 806.35; p = 0.001) and febrile periods (50.05 ± 79.38 h; CPS <100%, 120.00 ± 153.23; p = 0.002). Acceptance of CPS recommendations led to adequate peak levels. Acceptance of CPS recommendations led to lower direct costs (7,102.56 ± 9,898.19; CPS <100%, 19,629.94 ± 28,051.89; p <0.001). Calculated direct cost of the service was 85/patient.
AB - In a prospective, randomized study, 110 adults receiving aminogly-cosides were randomized to follow-up by a clinical pharmacokinetic service (CPS). Of the 110 patients, 35 accepted pharmacokinetic recommendations less than 100% of the time. The two groups were similar in age, sex, height, APACHE II score, and initial creatinine clearance. A cost-to-charge ratio was used to derive direct costs of hospitalization and calculate cost-benefit. Patients whose physicians accepted pharmacokinetic recommendations 100% of the time had shorter hospitalizations (322.67 ± 270.28 h; CPS <100%, 699.54 ± 806.35; p = 0.001) and febrile periods (50.05 ± 79.38 h; CPS <100%, 120.00 ± 153.23; p = 0.002). Acceptance of CPS recommendations led to adequate peak levels. Acceptance of CPS recommendations led to lower direct costs (7,102.56 ± 9,898.19; CPS <100%, 19,629.94 ± 28,051.89; p <0.001). Calculated direct cost of the service was 85/patient.
UR - http://www.scopus.com/inward/record.url?scp=0025091532&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025091532&partnerID=8YFLogxK
U2 - 10.1097/00007691-199009000-00004
DO - 10.1097/00007691-199009000-00004
M3 - Article
C2 - 2127325
AN - SCOPUS:0025091532
VL - 12
SP - 427
EP - 433
JO - Therapeutic Drug Monitoring
JF - Therapeutic Drug Monitoring
SN - 0163-4356
IS - 5
ER -